Dispelling Myths in the Value vs. Growth Debate with GMO's Ben Inker

Episode Summary

Executive Summary: Ben Inker argues that value investing remains compelling because long-run evidence, extreme current discounts, and rebalancing dynamics still favor value. He challenges common pro-growth narratives on rates, intangibles, traps, and secular growth, while emphasizing that valuation regimes matter and investors should focus on why an asset should earn a premium.

Main Topics: Long-term case for value investing (Priority: 5/5): Inker reviews global and Fama-French evidence showing value has historically outperformed over long horizons, and argues this is more plausibly due to persistent mispricing than a risk premium alone. Reopening and cyclicality misconceptions (Priority: 4/5): He explains that value’s recent strength was tied partly to reopening names and that, over time, value has not consistently outperformed in strong economies or underperformed in weak ones. Interest rates and duration myth (Priority: 5/5): Inker argues value and growth are much closer in duration than DCF intuition suggests once rebalancing is included, so rate changes should not be viewed as a simple value-vs-growth toggle. Limits of traditional valuation metrics (Priority: 4/5): He says price-to-book and unadjusted earnings are increasingly flawed due to intangibles, R&D expensing, and buybacks, but this argues for better value measures rather than abandoning value altogether. Value traps and growth traps (Priority: 5/5): He defines traps as companies whose fundamentals disappoint relative to expectations and shows growth traps are at least as common and potentially more damaging than value traps. Why high-expectation growth stocks usually disappoint (Priority: 5/5): Inker distinguishes a few exceptional winners like Amazon from the broader basket of expensive growth stocks, which historically underperform when bought at extreme sales multiples. Portfolio implications and current market positioning (Priority: 5/5): He warns that today’s rich U.S. equity and low bond yields imply lower future 60/40 returns, favoring cheaper non-U.S. equities and alternative diversifiers.

Key Arguments: Value has a strong long-term record across countries and over 100 years, so it should not be dismissed despite short-term underperformance. If growth were to outperform value forever, investors would have to systematically underprice growth for decades, which is hard to justify. The rebalancing effect matters: when stocks cease to be value or growth, that affects returns and makes naive duration arguments misleading. Value is not clearly more cyclical in performance; if anything, it has often done somewhat better during weak economic periods than strong ones. Traditional metrics like price-to-book are increasingly distorted by intangibles, R&D expensing rules, and buybacks, so adjusted measures are preferable. Growth traps exist and can underperform even more than value traps; growth investors are not immune to disappointment risk. A small number of extraordinary companies skew the narrative, but baskets of very expensive stocks have historically produced mediocre returns. Current valuation dispersion suggests value is unusually cheap, making future relative value returns more attractive than many investors assume. The classic 60/40 portfolio is unlikely to deliver historical real returns because both stocks and bonds are starting from expensive valuation and low-yield levels.

Data Points: Value outperformance history: ~100 years of evidence - Fama-French and country-level data cited as showing value outperformed over the long run Best growth months during value rallies: 6 of the 10 best months for growth vs. value - Occurred during the 1973-1977 and 2000-2003 value outperformance periods Value’s key outperformance periods: 1973-1977 and 2000-2003 - Two major value leadership regimes over the past 50 years Growth universe valuation cohort: Stocks trading above 10x sales - Used to examine high-expectation growth stock performance since 1980 Real return on 10x sales+ cohort: 4.4% real (1981 onward) - Performance of companies trading at 10x sales or more S&P 500 real return: 8.7% real (1981 onward) - Comparison benchmark for expensive growth cohort Relative wealth multiple: More than 6x - S&P 500 wealth accumulation versus 10x sales+ cohort Value discount percentile: 4th percentile of history - Current value discount versus growth, implying extreme cheapness Value vs growth valuation spread: Wider than normal; among widest in history - Current opportunity set for value investors Trap prevalence: About 30% of the universe on average - Share of companies that become value traps or growth traps in a given year Growth-stock duration: About 1 year longer in recent period - Growth stocks have stayed in the growth universe roughly five years instead of four U.S. GDP growth regime shift: Slower over the last 20 years / since about 2005 - Used to discuss lower-growth macro environment U.S. vs non-U.S. equity valuation gap: Largest in living memory / historically very wide - Motivates non-U.S. equity overweighting Current growth stock valuation: FANGs around mid-30s P/E - Used to contrast with 2000-era extreme valuations 2000-style speculation metric: Above 10x sales was over 10% of the U.S. market - One of only two times in history this happened, the other being today

Pivotal Quotes: "If growth is going to outperform value over the next 100 years, either it has to be riskier or have some other negative problem associated with it, for which I've heard no plausible argument." — Ben Inker: Explaining why perpetual growth leadership is hard to justify economically "The reality is, if you really want to understand what's going on with value or a market or any kind of investment, you got to go deeper than looking at the returns and look into the determinants of those returns." — Ben Inker: On evaluating strategies beyond headline performance "Whenever you're investing in something, make sure you understand why you should get paid for owning this asset... if that doesn't make sense for the guy on the other side, this is not going to be a sustainable strategy in the long run." — Ben Inker: Closing advice on distinguishing investing from speculation

Implications: Listeners should view value as a live, evidence-backed strategy, not a dead one. Current extremes in valuation, low bond yields, and weak 60/40 return prospects argue for disciplined rebalancing, better valuation measures, and a bias toward cheaper assets and diversifiers.